Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas

Histopathology

Volumn 55, Issue 3, 2009, Pages 346-352

  Fernandes, Raquel C M ^a   Bevilacqua, Jose L B ^b   Soares, Ibere C ^a,c   Siqueira, Sheila A C ^a   Pires, Luis ^a   Hegg, Roberto ^a   Carvalho, Filomena M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c Laboratory of Medical Investigation Unit 56   (Brazil)

Author keywords

Basal like carcinomas; Breast carcinoma; Gene expression profile; Histological grade; Immunohistochemical markers; Tissue microarray; Triple negative carcinomas

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; MIDDLE AGED; NECROSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 69549138175     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03380.x     Document Type: Article

References (25)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. 2005 16 1569 1583. (Pubitemid 41511089)
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
3. West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 2001 98 11462 11467.
4. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
5. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 2003 100 10393 10398.
6. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol. Biomarkers Prev. 2007 16 439 443.
7. Banerjee S, Reis-Filho JS, Ashley S et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006 59 729 735.
8. Tsuda H, Sakamaki C, Tsugane S et al. Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma. Jpn. J. Clin. Oncol. 1998 28 5 11. (Pubitemid 128527475)
9. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 2006 98 262 272.
10. Tavassoli FA, Devilee P. Tumours of the breast and female genital organs, 1st edn. Lyon : IARC Press, 2003 9 112.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 19 403 410.
12. Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007 131 18 43.
13. Motulsky H. Multiple comparisons. Intuitive biostatistics, Vol. 13. New York, NY : Oxford University Press, 1995 118 126.
14. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003 100 8418 8423.
15. Birnbaum D, Bertucci F, Ginestier C et al. Basal and luminal breast cancers: basic or luminous? Int. J. Oncol. 2004 25 249 258.
16. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998 433 119 129.
17. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 10 5367 5374.
18. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006 19 264 271.
19. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006 49 22 34.
20. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv. Anat. Pathol. 2007 14 358 373.
21. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007 9 R4.
22. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2003 95 1482 1485.
23. van de Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002 347 1999 2009.
24. van de Rijn RM, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002 161 1991 1996.
25. Rakha EA, El Sayed ME, Green AR et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007 50 434 438.